Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled Trial Evaluating a Two-Week Course of Zuranolone 50 mg when Co-Initiated with an Open-Label Selective Serotonin Reuptake Inhibitor (SSRI) in Patients with Major Depressive Disorder (MDD) with Additional Short-Term Follow-Up

Next Previous
Search
Trial Profile

A Placebo-Controlled Trial Evaluating a Two-Week Course of Zuranolone 50 mg when Co-Initiated with an Open-Label Selective Serotonin Reuptake Inhibitor (SSRI) in Patients with Major Depressive Disorder (MDD) with Additional Short-Term Follow-Up

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zuranolone (Primary) ; Serotonin uptake inhibitors
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Sage Therapeutics

    • Most Recent Events

    • 07 Apr 2020 According to a SAGE Therapeuntics media release, the company expects to initiate this study in 2020.
    • 26 Mar 2020 New trial record
    • 18 Mar 2020 According to a Sage Therapeutics media release, this trial includes an additional short-term follow-up.Topline data from this study is anticipated in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top